Regulators of innate immunity as novel targets for panviral therapeutics
Regulators of innate immunity as novel targets for panviral therapeutics
复制标题
DOI：
10.1016/j.coviro.2012.08.009
复制
发表时间：
2012-10-01
影响因子：
5.9
通讯作者：
Lamarre, Daniel
中科院分区：
文献类型：
--
作者：
Es-Saad, Salwa;Tremblay, Nicolas;Lamarre, Daniel
长期以来，干扰素（ifn）一直被用作一种免疫调节疗法，用于治疗大量急性和慢性病毒感染。然而，IFN疗法一直受到严重副作用的困扰。病原体识别受体（PRR）的发现使人们对免疫调节疗法的兴趣重燃。toll样受体（TLR）激动剂在激活免疫细胞和作为针对不同病毒的预防性疫苗的佐剂方面取得的成功为靶向免疫调节治疗铺平了道路。更好地表征病原体诱导的免疫紊乱和新发现的先天免疫调节因子现在有可能特异性地撤销普遍的颠覆机制，并通过引入比干扰素疗法副作用更小的全病毒疗法来改变抗病毒治疗。
Interferons (IFNs) have long been used as an immunomodulatory therapy for a large array of acute and chronic viral infections. However, IFN therapies have been plagued by severe side effects. The discovery of pathogen recognition receptors (PRR) rejuvenated the interest for immunomodulatory therapies. The successes obtained with Toll-like receptor (TLR) agonists in activating immune cells and as adjuvant for prophylactic vaccines against different viruses paved the way to targeted immunomodulatory therapy. Better characterization of pathogen-induced immune disorders and newly discovered regulators of innate immunity have now the potential to specifically withdraw prevailing subversion mechanisms and to transform antiviral treatments by introducing panviral therapeutics with less adverse effects than IFN therapies.